First Quarter 2021 Business Review

  • First quarter organic growth of 16.5% like-for-like
  • Molecular Biology up 19% over the quarter, with a slowdown in BIOFIRE® respiratory panels' demand in the US at period end
  • Strong 28% growth in Immunoassays, driven by COVID-related and certain emergency assays, ccombined with a confirmed recovery in routine parmeters
  • Solid 14% growth in Industrial Applications, Microbiology returns to growth
  • 2021 outlook: first-half and full-year 2021 sales guidance adjusted slightly, as the improvement in the health situation in the US is reducing demand for BIOFIRE® respiratory panels :

First-half sales are now expected to grow at around 10%, at constant exchange rates and scope of consolidation. In a very uncertain environment with contrasted evolution of the pandemic, full year sales are now expected to grow organically at neutral to mid-single digit rate. Despite the high level of uncertainty, the annual guidance for contributive operating income is maintained.

Contact us